MP201, a mitochondrial prodrug to protect the brain after traumatic injury
Mitochondrial Uncoupling Prodrug as a Translational Therapy for TBI
['FUNDING_R01'] · UNIVERSITY OF KENTUCKY · NIH-11030847
This project tests whether an experimental drug called MP201 can protect brain cells and help recovery after traumatic brain injury in adults.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-11030847 on ClinicalTrials.gov |
What this research studies
The team is developing MP201, a prodrug that gently shifts mitochondrial function to reduce harmful oxidative damage after a head injury. In lab and animal models they give carefully timed doses to see if MP201 preserves energy production, reduces cell damage, and raises protective factors like BDNF. The goal is to find the right dose and timing that work across species to support future human testing. Results will guide whether MP201 could move toward clinical trials for people with moderate to severe TBI.
Who could benefit from this research
Good fit: Adults (21+) who have experienced moderate to severe traumatic brain injury, especially in the acute period after injury, would be the likely candidates for this line of work.
Not a fit: People with only mild concussions, very old/chronic injuries, or those with medical conditions that make mitochondrial-targeting drugs unsafe (for example certain metabolic disorders or pregnancy) may not benefit or may be excluded.
Why it matters
Potential benefit: If successful, MP201 could become a treatment that reduces brain damage and improves cognitive recovery after moderate to severe traumatic brain injury.
How similar studies have performed: Related mitochondrial uncouplers have shown neuroprotection in animal studies and MP201 has shown promising preclinical results, but human effectiveness is not yet established.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SULLIVAN, PATRICK G — UNIVERSITY OF KENTUCKY
- Study coordinator: SULLIVAN, PATRICK G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired brain injury